A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy.

Trial Profile

A Multi-center, Randomized, Phase 3 Study of Sequential Pralatrexate Versus Observation in Patients With Previously Undiagnosed Peripheral T-cell Lymphoma Who Have Achieved an Objective Response Following Initial Treatment With CHOP-based Chemotherapy.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2017

At a glance

  • Drugs Pralatrexate (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Allos Therapeutics; Spectrum Pharmaceuticals
  • Most Recent Events

    • 16 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
    • 16 Oct 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 11 Aug 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top